1	Circulating SFRP5 levels are elevated in colorectal cancer and correlate with overall survival in stage II-
2	III disease
3	
4	Runhao Li ^{1,2} , Saifei Liu ^{1,2} , Kenny Yeo ^{2,3} , Suzanne Edwards ⁶ , Man Ying Li ^{2,3} , Ryan Santos ^{2,5} , Sima Kianpour
5	Rad ^{1,2} , Fangmeinuo Wu ^{1,2} , Guy Maddern ^{2,3} , Joanne Young ^{1,2,4} , Yoko Tomita ^{1,2,4} , Amanda Townsend ^{1,2,4} ,
6	Kevin Fenix ^{2,3} , Ehud Hauben ³ , Timothy Price ^{1,2,4} , Eric Smith ^{1,2,3,4}
7	
8	1. Solid Tumour Group, Basil Hetzel Institute for Translational Health Research, The Queen Elizabeth Hospital,
9	Woodville South, South Australia, 5011, Australia
10	2. Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, 5005, Australia
11	3. Discipline of Surgery, The University of Adelaide, Basil Hetzel Institute for Translational Health Research,
12	The Queen Elizabeth Hospital, Woodville South, South Australia, 5011, Australia
13	4. Medical Oncology, The Queen Elizabeth Hospital, South Australia, 5011, Australia
14	5. Viral Immunology Group, The University of Adelaide and Basil Hetzel Institute for Translational Health
15	Research, South Australia, 5011, Australia
16	6. School of Public Health, The University of Adelaide, Adelaide, South Australia, 5005, Australia
17	
18	Corresponding author: eric.smith@adelaide.edu.au.
19	ORCID identifier: https://orcid.org/0000-0003-2958-3492
20	
21	Contributing author: <u>runhao.li@adelaide.edu.au</u> .
22	ORCID identifier: https://orcid.org/0000-0001-5577-049X
23	
24	Keywords:
25	SFRP5; plasma biomarker; colorectal cancer; diagnosis; prognosis
26	
27	Abbreviations
28	area under the receiver operating characteristic (AUROC)
29	circulating SFRP5 (cSFRP5)
30	colorectal cancer (CRC)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 31 cysteine-rich domain (CRD)
- 32 enzyme-linked immunosorbent assay (ELISA)
- 33 mismatch repair deficiency (dMMR)
- 34 mismatch repair proficient (pMMR)
- 35 netrin-like domain (NTR)
- **36** secreted frizzled-related protein 5 (SFRP5)
- 37

38 Novelty and Impact

- 39 Our study unveils the clinical significance of circulating Secreted Frizzled-Related Protein 5 (cSFRP5) as a
- 40 potential diagnostic and prognostic marker in colorectal cancer (CRC). Analysing plasma from 731 participants,
- 41 we provide novel insights into cSFRP5, observing elevated levels in CRC compared to healthy controls, with the
- 42 highest concentrations in stage II. Importantly, elevated cSFRP5 levels correlate with prolonged survival in stage
- 43 II-III patients, suggesting a promising avenue for improving outcomes and reducing recurrence.

44 ABSTRACT

45 Secreted Frizzled-Related Protein 5 (SFRP5) modulates Wnt signalling pathways, affecting diverse biological 46 processes. We assessed the diagnostic and prognostic value of circulating SFRP5 (cSFRP5) in colorectal cancer 47 (CRC). Plasma cSFRP5 concentrations were measured using ELISA in healthy donors (n=133), individuals 48 diagnosed with CRC (n=449), colorectal polyps (n=85), and medical conditions in other organs including cancer, 49 inflammation, and benign states (n=64). Patients with CRC, polyps, and other conditions showed higher cSFRP5 50 levels than healthy individuals (p<0.0001). Receiver operating characteristic curves comparing healthy donors 51 with medical conditions, polyps, and CRC were 0.814 (p<0.0001), 0.763 (p<0.0001), and 0.762 (p<0.0001), 52 respectively. In CRC, cSFRP5 correlated with patient age (p<0.0001), tumour stage (p<0.0001), and histological 53 differentiation (p=0.0273). Levels peaked in stage II versus I (p<0.0001), III (p=0.0007), or IV (p<0.0001), and 54 were higher in stage III versus I (p=0.0007) and IV (p=0.0054), with no difference between I and IV. Elevated 55 cSFRP5 levels predicted longer overall survival in stage II-III CRC (univariate: HR 1.82, 95% CI 1.02-3.26, 56 p=0.024; multivariable: HR 2.34, 95% CI 1.12-4.88, p=0.015). This study confirms elevated cSFRP5 levels in

57 CRC and reveals a correlation between elevated cSFRP5 and overall survival in stage II-III disease.

58 INTRODUCTION

Colorectal cancer (CRC) represents a significant global healthcare challenge, ranking as the third most diagnosed cancer and a leading cause of cancer-related mortality ¹. With over 1.8 million reported cases and more than 0.9 million deaths in 2020 alone, there is urgency for the development of early detection strategies and to significantly improve treatment efficacy and survival rates. Enhancing screening methodologies, advocating regular screenings among high-risk populations, and developing precise, non-invasive screening technologies are imperative ^{2,3}.

64

65 Secreted frizzled-related protein 5 (SFRP5) belongs to the SFRP family, an evolutionarily conserved group of 66 extracellular glycoproteins crucial for modulating Wnt signalling pathways⁴. These pathways play pivotal roles 67 in various cellular processes, including embryonic development ⁵, tissue homeostasis, and the modulation of 68 tumour initiation, growth, and metastasis ^{6,7}. Structurally, SFRPs contain an amino-terminal signal peptide, a 69 cysteine-rich domain (CRD), and a carboxy-terminal netrin-like domain (NTR)⁸. The CRD is similar to the Wnt 70 ligand binding site found in Frizzled family of cell surface receptor proteins ⁹. The NTR domain is involved in 71 protein-protein interactions and is thought to contribute to the function of SFRPs ¹⁰. This structure enables SFRPs 72 to act as soluble antagonists of Wnt signalling by interacting with Wnt ligands and inhibiting activation of the 73 Frizzled receptors (reviewed in ¹¹).

74

SFRP5, specifically, has been shown inhibit multiple Wnt ligands such as Wnt5A and Wnt11, thereby regulating both canonical and non-canonical Wnt pathways ^{12,13}. Experimental evidence from murine disease models and studies on SFRP5 knockout mice suggests that secretion of SFRP5 by adipocytes prevents hepatic steatosis and metabolic dysfunction associated with liver fibrosis by modulating inflammatory cells within adipose tissue ^{12,14}. In humans, downregulation of SFRP5 contributes to proinflammatory conditions in visceral adipose tissue, potentially exacerbating obesity-related comorbidities ¹⁵.

81

Indeed, circulating SFRP5 (cSFRP5) has emerged as a potential biomarker in various diseases, participating in diverse pathological processes ¹⁶⁻¹⁸. Typically, individuals with metabolic disorders like obesity, insulin resistance, and diabetes exhibit reduced levels of cSFRP5 compared to healthy controls ¹⁶⁻¹⁹. Meanwhile, interventions leading to significant weight loss in overweight individuals are associated with increased cSFRP5 levels, further highlighting its role in metabolic regulation ²⁰⁻²². These findings collectively suggest that higher cSFRP5 levels are associated with reduced risk of metabolic disorders in humans. Interestingly, metabolic syndrome has been

shown to be associated with increased risk of liver metastasis in CRC patients ²³. Additionally, cSFRP5 has
 implications in cardiovascular diseases, with lower concentrations observed in individuals with arterial stiffness
 ²⁴, atherosclerosis ²⁵, coronary artery disease ^{26,27}, and hypertension ^{21,28}.

91

92 In contrast, the role of cSFRP5 in cancer remains understudied. Our previous study indicated that cSFRP5 was 93 elevated in CRC compared to non-CRC controls, and elevated cSFRP5 levels were associated with extended 94 disease-free survival among patients in stages I-III²⁹. Yet, limitations, such as small sample size and insufficient 95 control groups, hindered the comprehensive understanding of its potential. In this study, we measured cSFRP5 96 concentrations in an independent, retrospective, multi-centre cohort encompassing 133 healthy controls without 97 documented pathology, 449 patients with different stages of CRC, 85 individuals with colorectal polyps, and 64 98 individuals with other notable medical conditions in other organs including cancer, inflammation, and benign 99 states. Our primary objectives were to validate cSFRP5's diagnostic and prognostic potential and explore its 100 correlation with CRC progression-related clinical-pathological parameters and overall survival. Our secondary 101 objectives were to determine if cSFRP5 was altered in patients diagnosed with colorectal polyps and other medical 102 conditions in other organs including cancer, inflammation, and benign states.

103

104 MATERIALS AND METHODS

105 Patient plasma samples

All plasma samples were obtained from Victorian Cancer Biobank (Table 1) and were sourced from multiple
centres (Supplementary Table 1). The CRC samples were collected over a period from 1999 until 2021. All
individuals had fasted from the previous night until after blood collection.

109

110 SFRP5 enzyme-linked immunosorbent assay

The plasma cSFRP5 concentration was determined using a commercially sourced, commonly used enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's instructions (Cloud Clone Corp., TX, USA)²⁹. All ELISA kits used in this study were sourced from a single lot number (Lot# L210917454), with a detection range of 1.56-100 ng/mL. Plasma samples were diluted 1 in 2 in phosphate buffered saline (pH 7.0-7.2) and analysed in duplicate. The optical density at 450 nm was measured using iMark Microplate Absorbance Reader (Bio-Rad Laboratories, Inc., CA, USA), and the calculated cSFRP5 concentration was derived from the standard curve.

118

119 Statistical analysis

120 Statistical analyses were conducted using either Prism 10 for MacOS (GraphPad Software, Inc., CA, USA), SAS 121 On Demand for Academics (SAS Institute Inc., NC, USA), or the R package, survival v3.5. To assess differences 122 in cSFRP5 concentration between patient groups, we utilised Kruskal-Wallis with Dunn's multiple comparisons 123 test. Correlations between cSFRP5 concentration and various prognostic clinical-pathological parameters were 124 examined using the Mann-Whitney test. A linear regression model was employed to evaluate the relationship 125 between cSFRP5 concentration and patient group, tumour invasion stage, TNM group, as well as other prognostic 126 clinical-pathological parameters. This model was adjusted for potential confounding variables, including age and 127 sex. Assumptions crucial to the linear models, such as normality of residuals and homoscedasticity, were found 128 to be upheld through careful inspection of residual histograms and scatterplots of residuals against predicted 129 values. Univariate and multivariable Cox proportional hazard models were performed using R package, survival 130 v3.5, to assess relationship between overall survival, cSFRP5 concentration, TNM stage, age, sex, vascular or 131 perineural invasion, histological differentiation, and tumour site. A p≤0.05 was deemed statistically significant.

132

133 RESULTS

134 Patient cohorts

135 The study included 731 participants (Table 1), comprising 133 healthy donors without documented pathology 136 (Supplementary Table 2), 449 individuals diagnosed with CRC, 85 individuals with colorectal polyps 137 (Supplementary Table 3), and 64 individuals with other notable medical conditions in other organs 138 (Supplementary Table 4). The polyps group comprised the following subtypes: villous/tubulovillus (n=48), 139 adenoma/adenomatous (n=31), sessile serrated (n=2), hyperplastic (n=2), inflammatory (n=1), and Peutz Jegher 140 syndrome (n=1). The other notable medical conditions included patients diagnosed with cancer (n=4), chronic 141 inflammation (n=49), and benign diseases (n=11). The healthy participants consisted of more females (p<0.0001) 142 and were significantly younger (p<0.0001) (Supplementary fig. 1).

143

144 Circulating SFRP5 was elevated in colorectal cancer

145 The cSFRP5 concentration was significantly higher in CRC (mean 17.67 ng/mL, 95% confidence interval (95%

146 CI): 16.63-18.72 ng/mL) compared to healthy donors (9.26 ng/mL, 95% CI: 8.08-10.45 ng/mL; p<0.0001; Figure

147 1A). The area under the receiver operating characteristic (AUROC) curve for discriminating between CRC and

148 healthy donors was 0.762 (95% CI: 0.717 to 0.807; p<0.0001; Figure 1B). With regards to TNM stage, the cSFRP5 149 was significantly higher in all stages of CRC compared to healthy donors (Figure 1C). Notably, the cSFRP5 levels 150 were highest in stage II compared to either stage I (p<0.0001), III (p=0.0003), or IV (p<0.0001). The cSFRP5 was 151 significantly elevated in stage II compared to stage I (p=0.0007) and IV (p=0.0054). There was no significant 152 difference between stage I and IV. Recognising the notable variations in both age and sex among our patient cohorts and considering prior studies indicating the potential impact of these factors on cSFRP5 levels ^{30,31}, we 153 154 utilised a linear regression model to account for age and sex differences (Supplementary Table 5). Our analysis 155 revealed a correlation between age and increased cSFRP5 concentration, but no discernible disparity was observed 156 between males and females. Adjusting for age and sex did not alter the pattern of significant differences.

157

158 Circulating SFRP5 was elevated in colorectal polyps

Elevation of cSFRP5 was also observed in colorectal polyps, with a mean concentration of 17.34 ng/mL (95% CI:
15.00-19.69 ng/mL) compared to healthy donors (Supplementary fig. 2A; p<0.0001). The AUROC curve for
discriminating polyps from healthy donors was 0.763 (95% CI: 0.699 to 0.828; p<0.0001; Supplementary fig. 2B).
Furthermore, individuals with villous/tubulovillous (p<0.0001) and adenoma/adenomatous (p<0.01) polyps,
categorized as having high cancer progression risk, displayed significantly elevated cSFRP5 levels compared to
healthy controls (Supplementary fig. 2C).

165

166 Circulating SFRP5 was elevated in other disease states

167 Comparing individuals with various medical conditions to healthy donors revealed elevated cSFRP5 levels among 168 those with notable medical conditions, with a mean concentration of 21.23 ng/mL (95% CI: 17.84-24.62 ng/mL), 169 significantly higher than healthy donors (p<0.0001; Supplementary fig. 3A). The AUROC curve for 170 distinguishing between individuals with notable medical conditions and healthy donors yielded a value of 0.814 171 (95% CI: 0.746 to 0.882; p<0.0001; Supplementary fig. 3B). Moreover, cSFRP5 levels exhibited significant 172 increases in individuals with other cancers (p<0.0001), inflammation (p<0.0001), and miscellaneous benign 173 conditions (p<0.01) in other organs compared to healthy controls (Supplementary fig. 3C). However, it is 174 important to acknowledge that the sample size of these subgroups was limited, necessitating further validation 175 with larger cohorts.

176

177 Elevated circulating SFRP5 levels were not exclusive to colorectal cancer

178 We employed a linear regression model to adjust for age and sex differences when comparing patient groups 179 (Supplementary Table 6). The adjusted cSFRP5 concentration was notably higher in patients with significant 180 medical conditions (p<0.0001), colorectal polyps (p=0.0020), and CRC (p<0.0001). Particularly, cSFRP5 levels 181 were significantly elevated in patients with notable medical conditions compared to those with either colorectal 182 polyps (p=0.0130) or CRC (p=0.0027). However, no significant difference was observed between the polyps and 183 CRC groups. The AUROC curve for distinguishing between notable medical conditions and either CRC or polyps 184 was 0.596 (95% CI: 0.518 to 0.674; p=0.0127) and 0.613 (95% CI: 0.519 to 0.706; p=0.0188), respectively 185 (Supplementary Fig. 4). In summary, these findings suggest elevated cSFRP5 levels across various disease states, 186 including colorectal polyps and CRC.

187

Elevated circulating SFRP5 in colorectal cancer was associated with patient age, tumour stage and histological differentiation

190 In the patients with CRC, we investigated the correlations between the cSFRP5 concentration and different 191 clinical-pathological parameters (Table 2 and Supplementary fig. 5). We observed a significant increase in 192 cSFRP5 concentration with patient age (p<0.0001), TNM stage (p<0.0001), advanced depth of invasion 193 (p<0.0001), in the absence of distant metastasis (p=0.0049), and with poorly differentiated tumours (p=0.0273). 194 The cSFRP5 concentration was significantly higher in CRC patients with more invasive T3 and T4 primary 195 tumours compared to the less invasive T1 and T2 (Supplementary fig. 5A). Although there was an increase in 196 cSFRP5 concentration in CRC with mismatch repair deficiency (dMMR; Supplementary fig. 5I; p=0.0655), it did 197 not reach statistical significance. We did not detect variations in relation to sex, lymph node metastasis, vascular 198 or perineural invasion, diabetes, or hypertension in the patients with CRC.

199

200 Circulating SFRP5 correlates with overall survival in stage II-III colorectal cancer

We examined the relationship between cSFRP5 and overall survival of all CRC patients using Cox proportional hazard models (Supplementary Table 7). The median follow-up period was 4.3 years (range 0.08-20.7 years). Patients were stratified into low and high groups according to the median cSFRP5 concentration of 16.34 ng/mL observed among all CRC patients included in this study. When considering the entire CRC population encompassing stages I-IV, no significant association emerged between cSFRP5 concentration and overall survival, as revealed by both univariate (p=0.4866) and multivariable (p=0.9721) models (Supplementary Fig. 6 and Supplementary Table 7).

2	no	
Ζ	υo	

Ultimately, we examined the relationship between cSFRP5 and overall survival among stage II-III CRC patients,
who are at an elevated risk of disease recurrence. High cSFRP5 levels were associated with extended overall
survival (Figure 2 and Table 3; HR 1.82; 95% CI 1.02-3.26; p=0.0442). This correlation persisted in multivariable
analysis, accounting for confounding factors (HR 2.34; 95% CI 1.12-4.88; p=0.0229). These findings underscore
the prognostic relevance of cSFRP5 in CRC, particularly in the context of stage II-III disease.

214

215 DISCUSSION

This study investigated the levels of cSFRP5 across a diverse cohort, including healthy individuals, as well as those with CRC, colorectal polyps, and various other medical conditions. Elevated concentrations of cSFRP5 were identified in patients with CRC, polyps, and other significant illnesses, compared to the healthy controls. Notably, among CRC patients, cSFRP5 levels were highest in TNM stage II, followed by stage III, and were lowest in both stage I and IV. Furthermore, cSFRP5 levels exhibited an increase with patient age and were higher in the poorly differentiated tumours. Moreover, high cSFRP5 levels were associated with longer overall survival in the stage II-III CRC patients.

223

224 In our previous study, we highlighted the potential of cSFRP5 concentration as a diagnostic marker, effectively distinguishing CRC patients from those without CRC (AUROC 0.828, 95% CI 0.761-0.898)²⁹. In the current 225 226 study we reported that the cSFRP5 level comparing patients with CRC to healthy donors had a AUROC of 0.762 227 (95% CI: 0.717 to 0.807; p<0.0001). However, it is important to emphasise that we did not find a significant 228 difference between patients with colorectal polyps and those with CRC. Noteworthy is the fact that most of these 229 individuals with polyps have a high risk of developing into cancer. This suggests that cSFRP5 may hold value in 230 identifying individuals with high-risk polyps. However, our latest research revealed that individuals with other 231 notable medical conditions also exhibited elevated cSFRP5 levels. These findings raise concerns about the 232 exclusive use of cSFRP5 as a diagnostic biomarker for CRC population screening. However, it is important to 233 note that the notable medical conditions group consisted of patients admitted to hospitals for treatment of various 234 diseases, including cancer, inflammation, and benign states in organs other than the colorectum, and do not 235 necessarily represent the general population.

237 Regarding CRC prognosis, our findings indicate that cSFRP5 levels are most elevated in patients with TNM stage II tumours, followed by stage III, and are at their lowest in both stage I and IV. This was similar to our previous 238 239 findings in an independent CRC cohort, except that cSFRP5 levels were elevated in stage I, II and III compared 240 to stage IV²⁹. It is important to note that the previous study was constrained by a smaller sample size. Additionally, 241 we previously reported an association between elevated cSFRP5 and longer disease-free survival (HR 2.385; 95% 242 CI 1.181-4.816; p=0.015)²⁹. Unfortunately, the current study lacked data on disease recurrence for a 243 comprehensive analysis of disease-free survival. However, the current observation that elevated cSFRP5 in CRC 244 patients is linked to improved overall survival is consistent with the previous findings for disease-free survival. 245 Taken together, these findings suggest a favourable association between elevated cSFRP5 in CRC and survival 246 outcomes, particularly in those with stage II-III disease.

247

248 The explanation for the increased cSFRP5 observed in patients with CRC, polyps, and in the other disease states 249 remains largely unclear. In CRC, it is well established that SFRP5 transcript expression decreases due to promoter 250 DNA hypermethylation ^{29,32}, suggesting that the cancer cells are unlikely to be the origin of the heightened cSFRP5. 251 However, to date there have been no studies that have reported SFRP5 protein levels in colorectal tissues. Research 252 indicates that pancreatic cells express some of the highest levels of SFRP5 ^{29,33,34}. Elevated glucose and insulin 253 levels have been shown to decrease SFRP5 expression in pancreatic cells ³⁵, and insulin infusion leads to a 254 decrease in serum cSFRP5 ³⁶. Conversely, free fatty acids counteract the insulin-induced decrease in cSFRP5 ³⁶. 255 Furthermore, serum cSFRP5 is positively correlated with HDL-cholesterol and negatively correlated with 256 triglycerides and adiponectin ³⁶. Additionally, cSFRP5 is inversely associated with circulating levels of pro-257 inflammatory cytokines, including IL-6 and TNF α ³⁷. These collective observations suggest that systemic 258 disruptions in metabolism and inflammation drive changes in cSFRP5 levels, and potentially account for the 259 elevated concentrations observed in the study.

260

It is well accepted that SFRP5 binds Wnt ligands to antagonise Wnt signalling pathways ⁴. The Wnt signalling pathway is intricate and contingent on context. This pathway is indispensable for normal cellular processes, including cell proliferation, differentiation, and tissue homeostasis. However, dysregulation of the Wnt pathway is a pivotal factor in the development and progression of CRC. The non-canonical Wnt ligand, Wnt5a, is overexpressed in CRC and promotes cancer cell epithelial-mesenchymal transition, facilitating metastasis ^{38,39}. The primary sources of Wnt5a in CRC are fibroblasts and macrophages. Hirashima et al. demonstrated that Wnt5a

was expressed by cancer associated fibroblasts ⁴⁰. The Wnt5a+ cancer associated fibroblasts were significantly 267 268 associated with TNM stage, and recurrence. Subsequent in vitro analyses using human recombinant Wnt5a protein 269 revealed that cancer cell proliferation and migration were significantly increased by stimulation with Wnt5a. Liu 270 et al. identified that Wnt5a+ tumour-associated macrophages were associated with disease progression and poor 271 prognosis ⁴¹. Moreover, Wnt5a+ macrophages promoted CRC cell proliferation, invasion, and migration, and the 272 knockdown of Wnt5a significantly impaired the pro-tumour functions of tumour-associated macrophages. We 273 propose that the observed elevated levels of cSFRP5 inhibit Wnt5a-mediated disease progression. However, we 274 acknowledge that further studies are required.

275

276 We noticed higher cSFRP5 levels in mismatch repair deficient CRC compared to proficient ones, but it didn't 277 reach statistical significance. Unfortunately, only 244 out of 449 (54.3%) patients had their mismatch repair status 278 reported, as it was not routinely tested at these institutions. Mismatch repair deficient CRC tends to have more 279 mutations, generating neoantigens that attract immune cells to the tumour microenvironment. Meanwhile, SFRP5 280 by virtue of antagonising Wnt signalling pathways, has various effects on immune cells, influencing their 281 behaviour and differentiation ⁴². It can shift macrophages toward an anti-inflammatory type ¹² and affect the 282 balance between effector and regulatory T cells, contributing to immune stability ⁴³. Overall, SFRP5 appears to 283 play a role in modulating immune cell differentiation, affecting the balance between pro-inflammatory and anti-284 inflammatory responses. More research is needed to determine the specific role of cSFRP5 in shaping the tumour 285 immune cell microenvironment in CRC.

286

287 SFRP5 has garnered attention as a promising therapeutic target for various conditions, including metabolic 288 diseases ¹⁶. Notably, SFRP5 administration reversed hyperglycaemia and hepatic steatosis in multiple mouse models of metabolic dysfunction ¹². Lifestyle modifications leading to substantial weight loss in overweight 289 individuals have been reported to increase cSFRP5 levels 20-22. Exercise training induced calorie expenditure in 290 individuals with type 2 diabetes mellitus raised cSFRP5 levels ⁴⁴. Additionally, clinically prescribed drugs such 291 292 as the glucagon-like peptide-1 receptor agonist liraglutide have demonstrated the ability to elevate cSFRP5 levels 293 ³¹. Considering the observed association of elevated cSFRP5 with improved disease-free survival ²⁹ and overall 294 survival, interventions that elevate cSFRP5 and target Wnt signalling pathways could emerge as attractive options 295 for personalized medicine, particularly as an adjuvant therapy in individuals with stage II-III CRC with a 296 heightened risk of disease recurrence.

-	\sim	_
•	()	
	-	
_	_	

298 A significant limitation of this study is its retrospective design, which precludes adjustments to clinical practices. 299 Additionally, the absence of complete data for potentially important confounders, such as hypertension, obesity, 300 insulin resistance, and diabetes represent a noteworthy drawback. The unavailability of anthropometric 301 measurements, such as body weight, height, and waist circumference, further constrains the comprehensiveness 302 of our analysis. Moreover, the lack of information on therapeutic drug usage, such as chemotherapeutics and anti-303 inflammatories, limits our ability to adequately assess these factors. Moving forward, the validation of our findings 304 through prospective studies involving comprehensive CRC patient cohorts is crucial for advancing our 305 understanding of the diagnostic and prognostic potential of cSFRP5.

306

307 In conclusion, this study validated previous findings that cSFRP5 levels are elevated in CRC patients and revealed 308 that the highest cSFRP5 concentrations were detected in TNM stage II, followed by stage III, and the lowest in 309 stages I and IV. Importantly, we report the novel finding that elevated cSFRP5 levels correlated with extended 310 overall survival among stage II-III CRC patients, emphasizing its potential clinical significance as a prognostic 311 biomarker. Our findings suggest that augmenting cSFRP5 levels could potentially enhance survival outcomes for 312 stage II-III CRC patients, who are most vulnerable to disease recurrence.

313

314 ADDITIONAL INFORMATION

315 Acknowledgements

The authors wish to thank the study participants, nurses and clinicians from Victorian Cancer Biobank inMelbourne, Victoria, Australia.

318

319 Author Contributions

Conceptualization: Runhao Li, Timothy Price, Ehud Hauben and Eric Smith; Methodology: Runhao Li, Saifei
Liu, Sima Kianpour Rad, Ryan Santos, Man Ying Li, Fangmeinuo Wu; Formal analysis and investigation: Runhao
Li, Kenny Yeo, Suzanne Edwards, Eric Smith; Writing - original draft preparation: Runhao Li; Writing - review
and editing: Runhao Li, Kenny Yeo, Suzanne Edwards, Ryan Santos, Amanda Townsend, Yoko Tomita, Guy
Maddern, Joanne Young, Kevin Fenix, Ehud Hauben, Timothy Price, and Eric Smith; Funding acquisition:
Timothy Price, Ehud Hauben, and Eric Smith; Resources: Timothy Price, Ehud Hauben, and Eric Smith;
Supervision: Kevin Fenix, Timothy Price, and Eric Smith.

327	
328	Ethics approval and consent to participate
329	This study was performed in line with the principles of the Declaration of Helsinki, and in accordance with the
330	Australian Code for the Responsible Conduct of Research and the National Statement on Ethical Conduct in
331	Human Research. Approval was granted by the Central Adelaide Local Health Network Human Research Ethics
332	Committee (Date 21-Sep-2021/No. HREC/14/TQEHLMH/164). Informed consent was obtained from all
333	individual participants included in the study.
334	
335	Data availability
336	The data that support the findings of this study are available from the corresponding author upon reasonable
337	request.
338	
339	Competing Interests
340	The authors have no relevant financial or non-financial interests to disclose.
341	
342	Funding information
343	This work was supported by AusHealth (Grant number RES-SFRP-01). Author Runhao Li has received an
344	International PhD scholarship from The University of Adelaide.
345	
346	REFERENCES
347	1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence
348	and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. May 2021;71(3):209-249.
349	doi:10.3322/caac.21660
350	2. Kastrinos F, Kupfer SS, Gupta S. Colorectal Cancer Risk Assessment and Precision Approaches to
351	Screening: Brave New World or Worlds Apart? Gastroenterology. Apr 2023;164(5):812-827.
352	doi:10.1053/j.gastro.2023.02.021
353	3. Mikaeel RR, Symonds EL, Kimber J, et al. Young-onset colorectal cancer is associated with a personal

354 history of type 2 diabetes. Asia Pac J Clin Oncol. Feb 2021;17(1):131-138. doi:10.1111/ajco.13428

- Bovolenta P, Esteve P, Ruiz JM, Cisneros E, Lopez-Rios J. Beyond Wnt inhibition: new functions of
 secreted Frizzled-related proteins in development and disease. *J Cell Sci.* Mar 15 2008;121(Pt 6):737-46.
 doi:10.1242/jcs.026096
- 358 5. Komiya Y, Habas R. Wnt signal transduction pathways. Organogenesis. Apr 2008;4(2):68-75.
 359 doi:10.4161/org.4.2.5851
- 360 6. Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. *Nat Rev Cancer*. May
 361 2008;8(5):387-98. doi:10.1038/nrc2389
- 362 7. Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. *Nat Rev Cancer*. Jan
 363 2013;13(1):11-26. doi:10.1038/nrc3419
- 364 8. Jones SE, Jomary C. Secreted Frizzled-related proteins: searching for relationships and patterns.

365 Bioessays. Sep 2002;24(9):811-20. doi:10.1002/bies.10136

- 366 9. Bhat RA, Stauffer B, Komm BS, Bodine PV. Structure-function analysis of secreted frizzled-related
- 367 protein-1 for its Wnt antagonist function. J Cell Biochem. Dec 15 2007;102(6):1519-28. doi:10.1002/jcb.21372
- 368 10. Bányai L, Patthy L. The NTR module: domains of netrins, secreted frizzled related proteins, and type I
- 369 procollagen C-proteinase enhancer protein are homologous with tissue inhibitors of metalloproteases. *Protein Sci.*
- **370** Aug 1999;8(8):1636-42. doi:10.1110/ps.8.8.1636
- 371 11. Schulte G. International Union of Basic and Clinical Pharmacology. LXXX. The class Frizzled receptors.
- **372** *Pharmacol Rev.* Dec 2010;62(4):632-67. doi:10.1124/pr.110.002931
- **373** 12. Ouchi N, Higuchi A, Ohashi K, et al. Sfrp5 is an anti-inflammatory adipokine that modulates metabolic
- 374 dysfunction in obesity. *Science*. Jul 23 2010;329(5990):454-7. doi:10.1126/science.1188280
- 375 13. Li Y, Rankin SA, Sinner D, Kenny AP, Krieg PA, Zorn AM. Sfrp5 coordinates foregut specification and
- 376 morphogenesis by antagonizing both canonical and noncanonical Wnt11 signaling. Genes Dev. Nov 1
- **377** 2008;22(21):3050-63. doi:10.1101/gad.1687308
- Chatani N, Kamada Y, Kizu T, et al. Secreted frizzled-related protein 5 (Sfrp5) decreases hepatic stellate
 cell activation and liver fibrosis. *Liver Int*. Aug 2015;35(8):2017-26. doi:10.1111/liv.12757
- 380 15. Catalán V, Gómez-Ambrosi J, Rodríguez A, et al. Activation of noncanonical Wnt signaling through
- 381 WNT5A in visceral adipose tissue of obese subjects is related to inflammation. J Clin Endocrinol Metab. Aug
- **382** 2014;99(8):E1407-17. doi:10.1210/jc.2014-1191

- 383 16. Song Y, Ma Y, Zhang K, et al. Secreted frizzled-related protein 5: A promising therapeutic target for
 384 metabolic diseases via regulation of Wnt signaling. *Biochem Biophys Res Commun.* Oct 15 2023;677:70-76.
- 385 doi:10.1016/j.bbrc.2023.08.008
- Wang D, Zhang Y, Shen C. Research update on the association between SFRP5, an anti-inflammatory
 adipokine, with obesity, type 2 diabetes mellitus and coronary heart disease. *J Cell Mol Med.* Mar
 2020;24(5):2730-2735. doi:10.1111/jcmm.15023
- 389 18. Tong S, Ji Q, Du Y, Zhu X, Zhu C, Zhou Y. Sfrp5/Wnt Pathway: A Protective Regulatory System in
 390 Atherosclerotic Cardiovascular Disease. *J Interferon Cytokine Res.* Aug 2019;39(8):472-482.
 391 doi:10.1089/jir.2018.0154
- ·
- **392** 19. Nakamura K, Fuster JJ, Walsh K. Adipokines: a link between obesity and cardiovascular disease. J

393 *Cardiol.* Apr 2014;63(4):250-9. doi:10.1016/j.jjcc.2013.11.006

- 20. Tan X, Wang X, Chu H, Liu H, Yi X, Xiao Y. SFRP5 correlates with obesity and metabolic syndrome
- and increases after weight loss in children. *Clin Endocrinol (Oxf)*. Sep 2014;81(3):363-9. doi:10.1111/cen.12361

396 21. Yin C, Chu H, Li H, Xiao Y. Plasma Sfrp5 and adiponectin levels in relation to blood pressure among

397 obese children. J Hum Hypertens. Apr 2017;31(4):284-291. doi:10.1038/jhh.2016.76

- 398 22. Schulte DM, Müller N, Neumann K, et al. Pro-inflammatory wnt5a and anti-inflammatory sFRP5 are
 399 differentially regulated by nutritional factors in obese human subjects. *PLoS One.* 2012;7(2):e32437.
 400 doi:10.1371/journal.pone.0032437
- 401 23. Bhome R, Peppa N, Karar S, McDonnell D, Mirnezami A, Hamady Z. Metabolic syndrome is a predictor
 402 of all site and liver-specific recurrence following primary resection of colorectal cancer: Prospective cohort study
 403 of 1006 patients. *Eur J Surg Oncol.* Jul 2021;47(7):1623-1628. doi:10.1016/j.ejso.2020.12.016
- 404 24. Cho YK, Kang YM, Lee SE, et al. Effect of SFRP5 (Secreted Frizzled-Related Protein 5) on the WNT5A
 405 (Wingless-Type Family Member 5A)-Induced Endothelial Dysfunction and Its Relevance With Arterial Stiffness
- 406 in Human Subjects. Arterioscler Thromb Vasc Biol. Jun 2018;38(6):1358-1367. doi:10.1161/atvbaha.117.310649
- 407 25. Wang B, Pan Y, Yang G, et al. Sfrp5/Wnt5a and leptin/adiponectin levels in the serum and the periarterial
- 408 adipose tissue of patients with peripheral arterial occlusive disease. *Clin Biochem.* Jan 2021;87:46-51.
 409 doi:10.1016/j.clinbiochem.2020.11.002
- 410 26. Miyoshi T, Doi M, Usui S, et al. Low serum level of secreted frizzled-related protein 5, an anti-
- 411 inflammatory adipokine, is associated with coronary artery disease. *Atherosclerosis*. Apr 2014;233(2):454-459.
- 412 doi:10.1016/j.atherosclerosis.2014.01.019

- 413 27. Tong S, Du Y, Ji Q, et al. Expression of Sfrp5/Wnt5a in human epicardial adipose tissue and their
- 414 relationship with coronary artery disease. Life Sci. Mar 15 2020;245:117338. doi:10.1016/j.lfs.2020.117338
- 415 28. Li B, Yao Q, Guo S, et al. Type 2 diabetes with hypertensive patients results in changes to features of
- 416 adipocytokines: Leptin, Irisin, LGR4, and Sfrp5. Clin Exp Hypertens. 2019;41(7):645-650.
- **417** doi:10.1080/10641963.2018.1529779
- 41829.Kirana C, Smith E, Ngo DT, et al. High preoperative levels of circulating SFRP5 predict better prognosis
- 419 in colorectal cancer patients. *Future Oncol*. Nov 2020;16(31):2499-2509. doi:10.2217/fon-2020-0356
- 420 30. Yadav SS, Hussain S, Dwivedi P, Khattri S, Sawlani KK, Usman K. Assesement of serum Sfrp5/Wnt-
- 421 5a level and its utility in the risk stratification of treatment naïve patients with metabolic syndrome. J
- 422 Immunoassay Immunochem. Jan 2 2023;44(1):1-12. doi:10.1080/15321819.2022.2104125
- 423 31. Hu W, Li L, Yang M, et al. Circulating Sfrp5 is a signature of obesity-related metabolic disorders and is
 424 regulated by glucose and liraglutide in humans. *J Clin Endocrinol Metab.* Jan 2013;98(1):290-8.
 425 doi:10.1210/jc.2012-2466
- 426 32. Qi J, Zhu YQ, Luo J, Tao WH. Hypermethylation and expression regulation of secreted frizzled-related
 427 protein genes in colorectal tumor. *World J Gastroenterol*. Nov 28 2006;12(44):7113-7.
 428 doi:10.3748/wjg.v12.i44.7113
- 429 33. Single-cell transcriptomics of 20 mouse organs creates a Tabula Muris. *Nature*. Oct 2018;562(7727):367430 372. doi:10.1038/s41586-018-0590-4
- 431 34. Jones RC, Karkanias J, Krasnow MA, et al. The Tabula Sapiens: A multiple-organ, single-cell
 432 transcriptomic atlas of humans. *Science*. May 13 2022;376(6594):eabl4896. doi:10.1126/science.abl4896
- 433 35. Guan B, Li W, Li F, et al. Sfrp5 mediates glucose-induced proliferation in rat pancreatic β -cells. J
- 434 Endocrinol. May 2016;229(2):73-83. doi:10.1530/joe-15-0535
- 435 36. Rydzewska M, Nikołajuk A, Matulewicz N, Stefanowicz M, Karczewska-Kupczewska M. Serum
 436 secreted frizzled-related protein 5 in relation to insulin sensitivity and its regulation by insulin and free fatty acids.
- 437 Endocrine. Nov 2021;74(2):300-307. doi:10.1007/s12020-021-02793-z
- 438 37. Zhang Y, Ran Y, Kong L, et al. Decreased SFRP5 correlated with excessive metabolic inflammation in
- 439 polycystic ovary syndrome could be reversed by metformin: implication of its role in dysregulated metabolism. J
- 440 Ovarian Res. Jul 20 2021;14(1):97. doi:10.1186/s13048-021-00847-4

- 441 38. Gujral TS, Chan M, Peshkin L, Sorger PK, Kirschner MW, MacBeath G. A noncanonical Frizzled2
 442 pathway regulates epithelial-mesenchymal transition and metastasis. *Cell.* Nov 6 2014;159(4):844-56.
 443 doi:10.1016/j.cell.2014.10.032
- 444 39. Fuertes G, Del Valle-Pérez B, Pastor J, et al. Noncanonical Wnt signaling promotes colon tumor growth,
- 445 chemoresistance and tumor fibroblast activation. *EMBO Rep.* Apr 5 2023;24(4):e54895.
 446 doi:10.15252/embr.202254895
- 40. Hirashima T, Karasawa H, Aizawa T, et al. Wnt5a in cancer-associated fibroblasts promotes colorectal
- 448 cancer progression. *Biochem Biophys Res Commun.* Sep 3 2021;568:37-42. doi:10.1016/j.bbrc.2021.06.062
- 449 41. Liu Q, Yang C, Wang S, et al. Wnt5a-induced M2 polarization of tumor-associated macrophages via IL-
- 450 10 promotes colorectal cancer progression. Cell Commun Signal. Mar 30 2020;18(1):51. doi:10.1186/s12964-
- 451 020-00557-2
- 452 42. Haseeb M, Pirzada RH, Ain QU, Choi S. Wnt Signaling in the Regulation of Immune Cell and Cancer
 453 Therapeutics. *Cells*. Nov 3 2019;8(11)doi:10.3390/cells8111380
- 454 43. Pundkar C, Antony F, Kang X, et al. Targeting Wnt/β-catenin signaling using XAV939 nanoparticles in
- 455 tumor microenvironment-conditioned macrophages promote immunogenicity. *Heliyon*. Jun 2023;9(6):e16688.
- 456 doi:10.1016/j.heliyon.2023.e16688
- 457 44. Zadeh MAM, Afrasyabi S, Mohamadi ZA. The effects of exercise training induced calories expenditure
- 458 on type 2 diabetes related cardio metabolic physiological parameters and adipocytokines. J Diabetes Metab
- 459 Disord. Dec 2022;21(2):1219-1231. doi:10.1007/s40200-021-00808-0





463 Figure 1: (A) Concentration of cSFRP5 in healthy donors (H) (n=133) and patients with colorectal cancer (CRC)
464 (n=449). (B) AUROC curve for cSRFP5 concentration comparing H to CRC. (C) Concentration of cSFRP5 in
465 healthy donors (H) (n=133) and CRC patients by TNM stage I (n=147), stage II (n=103), stage III (n=109), and
466 stage IV (n=90). The data are the mean ± SD. Kruskal-Wallis with Dunn's multiple comparisons were used,
467 ****p<0.0001, *p<0.05.



468

469 Figure 2: Kaplan-Meier survival curve for overall survival in patients with stage II-III colorectal CRC (n=212)

470 dichotomized into low (≤ 16.34 ng/mL), or high (>16.34 ng/mL) cSFRP5 concentration.

471 TABLES

472 Table 1 Summary of participants in this study

Group	n	Female (%)	Median age, years (range)
Healthy (H)	133	86 (64.7%)	42 (16-80)
Notable medical conditions (D)	64	15 (23.4%)	60 (25-88)
Colorectal polyps (P)	85	40 (47.1%)	66 (22-88)
Colorectal Cancer (CRC)			
Stage I	147	60 (40.8%)	68 (34-91)
Stage II	103	40 (38.8%)	68 (32-95)
Stage III	109	36 (33.0%)	68 (28-89)
Stage IV	90	36 (40.0%)	57.5 (25-82)
CRC Total	449	172 (38.3%)	66 (25-95)
Total	731	313 (42.8%)	63 (16-95)

474 Table 2 cSFRP5 concentration in CRC with various prognostic clinical-pathological parameters

Clinical parameters	n	Mean cSFRP5 (95% CI)	p value
Age*	449		<0.0001
Sex			
Female	172	17.65 (15.97-19.33)	0.3927
Male	277	17.69 (16.35-19.03)	
TNM stage			
Ι	147	14.18 (12.63-15.74)	
II	103	23.94 (21.08-26.80)	<0.0001
III	109	28.68 (16.96-20.41)	
IV	90	14.98 (13.26-16.70)	
Tumour invasion (T-stage)			
T1	54	15.19 (12.11-18.27)	
T2	103	13.72 (12.10-15.34)	<0.0001
Т3	175	21.15 (19.26-23.03)	
T4	58	19.15 (16.34-21.95)	
Lymph node metastasis (N-stage)			
N0	260	18.06 (16.50-19.62)	0.2122
N1/N2	137	17.99 (16.49-19.49)	0.2122
NR	52		
Distant metastasis (M-stage)			
M0	359	18.35 (17.13-19.57)	0.0049
M1	90	14.98 (13.26-16.70)	
Vascular or perineural invasion			
Negative	381	17.43 (16.28-18.57)	0.0980
Positive	68	19.07 (16.56-21.58)	
Histological differentiation			
Low (Grade 1-2)	374	17.06 (16.03-18.09)	0.0273
High (Grade 3-4)	75	20.74 (17.22-24.27)	
Tumour site			
Colon	311	18.07 (16.72-19.42)	0.7549
Rectum	138	16.78 (15.25-18.31)	
Mismatch repair status			
pMMR	220	18.21 (16.79-19.63)	0.0655
dMMR	24	25.20 (15.80-34.60)	0.0055
NR	205		
Diabetes			
Negative	130	17.66 (15.40-19.91)	0 2007
Positive	94	18.47 (16.43-20.50)	0.2007
NR	225		

Clinical parameters	n	Mean cSFRP5 (95% CI)	p value
Hypertension			
Negative	26	16.20 (13.93-18.46)	0.9106
Positive	198	18.23 (16.50-19.96)	0.8190
NR	225		
*Analysed as a continuous variable.			
Mismatch repair deficiency (dMMR)			
Mismatch repair proficient (pMMR)			
Not recorded (NR)			

95% confidence interval (95% CI)

480	Table 3 Univariate and multivariable analysis	s of overall survival in stage II-III CRC
-----	---	---

Predictor	Univariate		Multivariable		
-	Hazard ratio (95% CI)	p value	Hazard ratio (95% CI)	p value	
cSFRP5					
High (>16.34 ng/mL)	1		1		
Low (≤16.34 ng/mL)	1.82 (1.02-3.26)	0.0442	2.34 (1.12-4.88)	0.0229	
Age*	1.06 (1.03-1.09)	<0.001	1.07 (1.03-1.10)	<0.001	
Sex					
Male	1		1		
Female	0.80 (0.44-1.45)	0.4609	0.81 (0.43-1.53)	0.5210	
TNM stage					
II	1		1		
III	1.41 (0.80-2.47)	0.2366	1.18 (0.61-2.27)	0.6151	
Differentiation					
Low (Grade 1-2)	1		1		
High (Grade 3-4)	1.17 (0.63-2.16)	0.6203	1.03 (0.53-1.92)	0.9920	
Vascular or					
perineural invasion					
Negative	1		1		
Positive	1.67 (0.89-3.11)	0.1065	1.78 (0.89-3.55)	0.1003	
Tumour site					
Colon	1		1		
Rectum	0.79 (0.43-1.43)	0.4344	0.95 (0.51-1.77)	0.8839	

481 **Analysed as a continuous variable.*



483 Supplementary fig. 1: Age and gender of individuals in different groups. (A) Comparison of age in healthy
484 donors without documented pathology (H) (n=133), patients with other notable medical conditions (D) (n=64),
485 colorectal polyps (P) (n=85), or colorectal cancer (CRC) patients (n=449): stage I (n=147), stage II (n=103), stage
486 III (n=109), and stage IV (n=90). Data as mean ± SD. Kruskal-Wallis with Dunn's multiple comparisons were
487 used, ****p<0.0001, **p<0.001, *p<0.05. (B) Comparison of gender ratio between different groups.



488

Supplementary fig. 2: Concentration of cSFRP5 from healthy donors (H) and patients with colorectal polyps (P)
(A) Comparison of cSFRP5 concentration in H (n=133) and P (n=85). (B) AUROC curve for cSRFP5
concentration comparing H to P. (C) Concentration of cSFRP5 in healthy donors (H) and patients with
villous/tubulovillous (n=48), adenoma/adenomatous (n=31), sessile serrated (n=2), and other (n=4) types of
colorectal polyps. The data are the mean ± SD. Kruskal-Wallis with Dunn's multiple comparisons were used,
****p<0.0001, **p<0.01.





Supplementary fig. 3: Concentration of SFRP5 from healthy donors (H) and other notable medical conditions (D). (A) Comparison of cSFRP5 concentration in H (n=133) and D (n=64). (B) AUROC curve for cSRFP5 concentration comparing H to D. (C) Concentration of cSFRP5 in healthy donors (H) (n=133) and patients with different types of notable medical conditions or significant disease by benign diseases (n=11), chronic inflammation (n=49), and cancer (n=4). The data are the mean \pm SD. Kruskal-Wallis with Dunn's multiple comparisons were used, ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05.



502

503 Supplementary fig. 4: cSFRP5 AUROC curves for (A) colorectal cancer polyps (P) (n=85) versus colorectal 504 cancer (CRC) (n=449), (B) other notable medical conditions (D) (n=64) versus CRC (n=449), and (C) P (n=85)

505 versus D (n=64).





507 Supplementary fig. 5: Concentration of cSFRP5 by various prognostic clinical-pathological parameters. (A) 508 primary tumour invasion (T) stage. T1: tumour invades submucosa (n=54), T2: tumour invades muscularis propria 509 (n=103), T3: tumour invades through the muscularis propria into peri-colorectal tissues (n=175), and T4: tumour 510 directly invades or is adherent to other organs or structures (n=58). (B-K) cSRFP5 concentration comparison of 511 sex, lymph node metastasis, distant metastasis, vascular or perineural invasion (VPNI), differentiation, tumour 512 site, mismatch repair status, diabetes, and hypertension respectively. The data are the mean \pm SD. A linear 513 regression model was used for multiple comparisons, ****p<0.0001, ***p<0.001, **p<0.001, **p<0.05.







515 Supplementary fig. 6: The Kaplan-Meier survival curves for overall survival in patients with colorectal cancer 516 based on low and high cSFRP5 expression levels. (A) All patients (n=449), (B) Stage I (n=147), (C) Stage II 517 (n=103), (**D**) Stage III (n=109), (**E**) Stage IV (n=90). Patients are dichotomized into low (≤16.34 ng/mL), or high 518 (>16.34 ng/mL) cSFRP5 concentration, and survival curve were compared using Kaplan-Meier plots.

Hospital / Institution	Healthy (H)	Notable medical conditions (D)	Colorectal polyps (P)	Colorectal Cancer (CRC)	Total (n)
Austin Hospital (AH)	21	26	8	85	140
Barwon Health (BH)	-	-	3	1	4
Eastern Health (EH)	6	11	20	184	221
Monash Health (MH)	-	-	4	5	9
North Health (NH)	2	6	5	3	16
Peter MacCallum Cancer Centre (PM)	104	21	15	86	226
Royal Melbourne Hospital (RMH)	-	-	13	20	33
Western Health (WH)	-	-	17	65	82
Total	133	64	85	449	731

519 Supplementary Table 1 Summary of all samples from different institutions

521	Supplementary Table 2	Summary of healthy	donors without	t significant docume	ented pathology
-----	-----------------------	--------------------	----------------	----------------------	-----------------

Group	n	Female (%)	Median age, years (range)
Healthy	75	28 (37.3%)	41 (16-80)
Prophylactic mastectomy	37	37 (100%)	41 (22-60)
Breast reduction	19	19 (100%)	43 (18-64)
Uterus endocervical polyp	1	1 (100%)	63
Lipoma	1	1 (100%)	68
Total	133	86 (50.0%)	42 (16-80)

523 Supplementary Table 3 Summary of patients with colorectal polyps

Polyp type	n
Villous/tubulovillous adenoma	48
Adenoma/adenomatous	31
Sessile serrated	2
Hyperplastic	2
Inflammatory	1
Peutz Jegher syndrome	1
Total	85

525 **Supplementary Table 4** Summary of patients with notable medical conditions

Classification	Notable medical conditions	n	Total		
Cancer	Lobectomy for lung cancer	1			
	Osteosarcoma; abscess	1	. 4		
	Renal oncocytoma	1			
	Transitional cell carcinoma	1			
	Active chronic colitis/proctitis	1			
	Bladder wall lesions	1			
	Bronchiolitis & pneumonia	11	11		
	Cholangitis and pancreatitis	1			
	Cholecystitis and cholelithiasis	8			
	Cirrhotic appearance	1			
	Crohn's disease	2			
	Diverticulosis	4			
	Duodenal oedema and mild inflammation	1			
	Hashimoto's (autoimmune) thyroiditis	3			
Changing inflormation	Interstitial cystitis	1	40		
Chronic inflammation	Lung cavitating lesion	1	49		
	Necrotizing granulomatous lymphadenitis	1			
	Non-necrotising granulomatous inflammation	1			
	Peritoneal abscess	1			
	Pleural bloodstained fluid	1			
	Prostatitis	5			
	Reactive lymphoid hyperplasia	1			
	Resection of ileoanal pouch	1			
	Right hemicolectomy: ulceration	1			
	Sinus histiocytosis	1			
	Splenectomy, autoimmune hemolytic anaemia	1			
_	Meckel's diverticulum	1			
	Peri-rectal bleeding	1			
	Haematuria, likely benign prostatic hyperplasia	1	11		
	Benign multinodular goitre	2			
Benign disease	Multiple simple bilateral renal cysts	1			
	Nodular and prostatic hyperplasia				
	Anthracosis	1			
	Haematoma	1			
	Hydronephrosis	1	1		

Predictor	Comparison	Unadjusted		Adjusted by age and sex	
		Mean difference (95% CI)	p value	Mean difference (95% CI)	p value
	I vs II	-9.76 (-12.42, -7.10)	<0.0001	-9.81 (-12.43, -7.20)	<0.0001
	I vs III	-4.50 (-7.12, -1.89)	0.0007	-4.65 (-7.23, -2.07)	0.0004
TNM stars	I vs IV	-0.80 (-3.57, 1.97)	0.5725	-2.21 (-5.03, 0.60)	0.1234
TINIVI stage	II vs III	5.26 (2.41, 8.10)	0.0003	5.16 (2.36, 7.96)	0.0003
	II vs IV	8.96 (5.98, 11.95)	<0.0001	7.60 (4.58, 10.61)	<0.0001
	III vs IV	5.10 (1.69, 8.55)	0.0054	3.70 (0.76, 6.65)	0.0138
Age	Continuous			1.69 (0.83, 2.56)	<0.0001
Sex	Female vs Male			0.08 (-2.16, 2.32)	0.9444

527 Supplementary Table 5 Linear regression model of cSFRP5 (continuous) versus TNM stage

Unadjusted Adjusted by age and sex Predictor Comparison Mean difference (95% CI) Mean difference (95% CI) p value p value < 0.0001 H vs D -11.97 (-15.17, -8.76) < 0.0001 -9.36 (-12.72, -6.00) -8.08 (-11.00, -5.15) < 0.0001 -4.97 (-8.12, -1.81) 0.0020 H vs P H vs CRC -8.41 (-10.49, -6.33) < 0.0001 -5.07 (-7.54, -2.60) < 0.0001 Patient group D vs P 3.89 (0.40, 7.37) 0.0288 4.39 (0.93, 7.86) 0.0130 D vs CRC 3.56 (0.74, 6.37) 4.29 (1.48, 7.10) 0.0132 0.0027 P vs CRC -0.33 (-2.82, 2.16) 0.7949 -0.10 (-2.56, 2.36) 0.9342 Continuous 1.35 (0.78, 1.92) < 0.0001 Age Female vs Male -0.94(-2.53, 0.66)0.2498 Sex

529 Supplementary Table 6 Linear regression model of cSFRP5 (continuous) versus patient groups

Predictor	Univariate		Multivariable		
-	Hazard ratio (95% CI)	p value	Hazard ratio (95% CI)	p value	
cSFRP5*	1.01 (0.99-1.02)	0.4866	0.99 (0.98-1.02)	0.9721	
Age*	1.03 (1.02-1.05)	<0.001	1.06 (1.04-1.08)	<0.001	
Sex					
Male	1		1		
Female	0.86 (0.61-1.22)	0.4066	1.06 (0.74-1.53)	0.7331	
TNM stage					
Ι	1		1		
II	1.33 (0.78-2.27)	0.2894	1.24 (0.70-2.19)	0.4526	
III	1.91 (1.13-3.21)	0.0151	1.69 (0.94-3.05)	0.0943	
IV	5.56 (3.55-8.72)	<0.001	8.58 (5.16-14.25)	<0.001	
Differentiation					
Low (Grade 1-2)	1		1		
High (Grade 3-4)	1.23 (0.81-1.86)	0.3286	1.15 (0.74-1.79)	0.5442	
Vascular or					
perineural invasion	1		1		
Negative	1	~0.001	1	0.0402	
Positive	2.27 (1.51-5.42)	<0.001	1.39 (1.02-2.49)	0.0402	
Tumour site					
Colon	1		1		
Rectum	0.72 (0.49-1.07)	0.1049	1.25 (0.81-1.91)	0.3084	

531 Supplementary Table 7 Univariate and multivariable analysis of overall survival for all CRC patients

532 **Analysed as a continuous variable.*